These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 28025840)

  • 1. Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients.
    Angelison L; Almer S; Eriksson A; Karling P; Fagerberg U; Halfvarson J; Thörn M; Björk J; Hindorf U; Löfberg R; Bajor A; Hjortswang H; Hammarlund P; Grip O; Torp J; Marsal J; Hertervig E;
    Aliment Pharmacol Ther; 2017 Feb; 45(4):519-532. PubMed ID: 28025840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
    Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
    Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
    Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
    Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study.
    Gornet JM; Couve S; Hassani Z; Delchier JC; Marteau P; Cosnes J; Bouhnik Y; Dupas JL; Modigliani R; Taillard F; Lemann M
    Aliment Pharmacol Ther; 2003 Jul; 18(2):175-81. PubMed ID: 12869077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
    Jakobovits SL; Jewell DP; Travis SP
    Aliment Pharmacol Ther; 2007 May; 25(9):1055-60. PubMed ID: 17439506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
    Taxonera C; Barreiro-de Acosta M; Calvo M; Saro C; Bastida G; Martín-Arranz MD; Gisbert JP; García-Sánchez V; Marín-Jiménez I; Bermejo F; Chaparro M; Ponferrada Á; Martínez-Montiel MP; Pajares R; de Gracia C; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
    Dig Dis Sci; 2015 Oct; 60(10):3075-84. PubMed ID: 26044830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
    Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inpatient infliximab is ineffective at preventing colectomy for steroid refractory extensive colitis.
    Andrew RE; Lauria A; Puleo FJ; Berg A; Stewart DB
    J Surg Res; 2017 Nov; 219():18-24. PubMed ID: 29078879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis.
    Willert RP; Lawrance IC
    World J Gastroenterol; 2008 Apr; 14(16):2544-9. PubMed ID: 18442203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study.
    García-Bosch O; Aceituno M; Ordás I; Etchevers J; Sans M; Feu F; Panés J; Ricart E
    Dig Dis Sci; 2016 Jul; 61(7):2051-9. PubMed ID: 26921082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
    Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
    J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.
    Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Sociale O; Papa A; De Vitis I; Rapaccini GL; Guidi L
    Inflamm Bowel Dis; 2013 Apr; 19(5):1065-72. PubMed ID: 23448790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.
    Halpin SJ; Hamlin PJ; Greer DP; Warren L; Ford AC
    World J Gastroenterol; 2013 Feb; 19(7):1091-7. PubMed ID: 23467174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis.
    Sebastian S; Myers S; Argyriou K; Martin G; Los L; Fiske J; Ranjan R; Cooper B; Goodoory V; Ching HL; Jayasooriya N; Brooks J; Dhar A; Shenoy AH; Limdi JK; Butterworth J; Allen PB; Samuel S; Moran GW; Shenderey R; Parkes G; Lobo A; Kennedy NA; Subramanian S; Raine T
    Aliment Pharmacol Ther; 2019 Sep; 50(6):675-683. PubMed ID: 31456297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study.
    Nasuno M; Miyakawa M; Tanaka H; Motoya S
    Digestion; 2017; 95(1):67-71. PubMed ID: 28052276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab efficacy in pediatric ulcerative colitis.
    Eidelwein AP; Cuffari C; Abadom V; Oliva-Hemker M
    Inflamm Bowel Dis; 2005 Mar; 11(3):213-8. PubMed ID: 15735427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis.
    Church PC; Ho S; Sharma A; Tomalty D; Frost K; Muise A; Walters TD; Griffiths AM
    J Crohns Colitis; 2019 Aug; 13(8):982-989. PubMed ID: 30715240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.
    Laharie D; Bourreille A; Branche J; Allez M; Bouhnik Y; Filippi J; Zerbib F; Savoye G; Vuitton L; Moreau J; Amiot A; Cosnes J; Ricart E; Dewit O; Lopez-Sanroman A; Fumery M; Carbonnel F; Bommelaer G; Coffin B; Roblin X; van Assche G; Esteve M; Farkkila M; Gisbert JP; Marteau P; Nahon S; de Vos M; Lambert J; Mary JY; Louis E;
    Gut; 2018 Feb; 67(2):237-243. PubMed ID: 28053054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.